| Title: | Quinoline Derivatives as 5-HT6 Receptor PET Ligands | |||
| Patent/Patent Application Number: | US-20130343993-A1 | Publication date: | December 26, 2013 | |
| Priority Application: | US-20130343993-A1 | Priority date: | January 08, 2012 | |
| Inventors: | Black, L. A. | |||
| Assignee Company: | AbbVie Inc. USA | |||
| Disease Area: | Alzheimer’s Disease, deficits in memory, cognition, and learning | Biological Target: | 5-HT6 receptor | |
| Summary: | This application claims a series of quinolines for treating or preventing a condition or disorder related to memory deficits such as Parkinson’s disease, Alzheimer’s disease, mild cognitive impairment, depression, and anxiety. The invention claims also radiolabeled quinolines useful as diagnostic tools as 5-HT6 receptor PET ligands. | |||
| Important Compound Classes: |  |
|||
| Key Structures: |  |
|||
| Biological Assay: | Compounds were evaluated in 5-HT6, 5-HT2A, and 5-HT2B receptor binding assays and against a panel of 78 receptors/drug targets. | |||
| Biological Data: |  |
|||
The authors declare no competing financial interest.